Your gateway to the world of medicine
Cancer News
About Us
Health Professionals
Patients and public
Contact Us
Disclaimer Archives of lung-cancer-blog

Go Back to the main lung-cancer-blog

Subscribe To Health Blog RSS Feed  RSS content feed What is RSS feed?

Archives Of Lung-cancer-blog From Medicineworld.Org

July 3, 2006, 9:25 AM CT

Milk Thistle Against Lung Cancer

Milk Thistle Against Lung Cancer
A derivative of milk thistle has shown a significant ability to reduce lung tumour growth in mice say scientists.

"We have been studying milk thistle components, silymarin and silibinin, to examine their efficacy and mechanisms against different cancers for over a decade," noted lead investigator Dr Rana Singh.

In the current tests, mice were given silibinin as part of their diet.

Those that had received the supplement developed on average two tumours per animal, while an untreated control group developed an average of 27.

The scientists also noted that silibinin seemed able to reduce the number of blood vessels supplying nutrients to the tumours.

"We expect soon after that clinical trials with silibinin in lung cancer patients will be planned," added Dr Singh.

Patient trials of the effects of silibinin on prostate cancer are currently underway.

The study noted that the derivative used was created artificially and bore no resemblance to milk thistle dietary supplements.

The research was conducted by the University of Colorado and reported in the Journal of the National Cancer Institute.........

Posted by: Scott      Permalink         Source

June 19, 2006, 9:24 PM CT

Suggest your News Item To Medicineworld

Suggest your News Item To Medicineworld
As you are aware we are the leading publishers of health news on the web. We publish news items in various forms including numerous blogs and news items. We invite you to participate in our new collection.

We are looking for quality news items that would be interesting to our readers. Now you may suggest the news item from your site to be included at Inclusion of news item at our site get instantaneous attention since the item is illustrated from various blog posts. Addition of pictures to the item adds additional attraction to your news item. Inclusion in the site brings quality links and visitors to your site.

If you have an interesting news item related to health, share it with and we share it with the world.

Suggest your News Item To Medicineworld........

Posted by: Janet      Permalink

June 12, 2006, 8:55 PM CT

New Test Identifies Patients Who Benefit From Targeted Cancer Drugs

New Test Identifies Patients Who Benefit From Targeted Cancer Drugs
The Weisenthal Cancer Group today announced that clinical data published at the annual meeting of the American Society of Clinical Oncology (ASCO) show that a new laboratory test it has developed accurately identified patients who would benefit from therapy with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva®, Genentech). The new test, called the EGFRx- assay, predicted accurately for the survival of patients treated with the targeted drugs. The finding is important because the EGFRx- test, which can also be applied to a number of emerging targeted cancer drugs, could help to help to solve the growing problem of knowing which patients should receive costly, new therapys that can have harmful side-effects and which work for some but not all cancer patients who receive them.

Larry Weisenthal, M.D., Ph.D., a medical oncologist and developer of the EGFRx assay explains that the new test relies upon what he calls "Whole Cell Profiling" in which living tumor cells are removed from an individual cancer patient and exposed in the laboratory to the new drugs. A variety of metabolic and apoptotic measurements are then used to determine if a specific drug was successful at killing the patient's cancer cells. The whole cell profiling method differs from other tests in that it assesses the activity of a drug upon combined effect of all cellular processes, using several metabolic and morphologic endpoints. Other tests, such as those which identify DNA or RNA sequences or expression of individual proteins often examine only one component of a much larger, interactive process.........

Posted by: Janet      Permalink         Source

June 7, 2006, 0:11 AM CT

Lung Cancer Overdiagnosis

Lung Cancer Overdiagnosis
Screening may lead to overdiagnosis of lung cancer, a study reports in the June 7 issue of the Journal of the National Cancer Institute.

Screening for cancer can find tumors that might not otherwise have been diagnosed in a person's lifetime, a situation called overdiagnosis. Overdiagnosis wastes health care resources. Tests and therapy resulting from overdiagnosis can lead to substantial toxicity and even premature death in patients.

Pamela M. Marcus, Ph.D., of the National Cancer Institute in Bethesda, Md., and his colleagues surveyed 7,118 participants in the Mayo Lung Project for information on their lung cancer diagnosis, health, and smoking history, and chest scan results after the study's initial follow-up in July 1983. The patients in the initial project had been randomly placed in two groups, one of which underwent multiple screening chest x-rays and spectrum tests used to identify lung cancer.

The authors identified a total of 585 cancers in the patients in the screened arm and 500 cancers in the group that was not screened. They report that the 85 more cancers found in screened patients suggests that screening can lead to lung cancer overdiagnosis.

"Eventhough the magnitude of overdiagnosis in chest x-ray screening appears to be modest, the very real and deleterious role that overdiagnosis plays in mass screening can not be discounted. The newest imaging technologies can detect very small lung abnormalities, but these abnormalities may be clinically unimportant. The question remains as to whether early detection of lung cancer through mass screening results in a net benefit to the public's health." the authors write.........

Posted by: Scott      Permalink         Source

June 5, 2006, 9:17 PM CT

New Predictor For Lung Cancer

New Predictor For Lung Cancer
Research from the Ireland Cancer Center of University Hospitals of Cleveland has found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to therapy. Afshin Dowlati, MD, hematologist/ oncologist at the Ireland Cancer Center, presented this study June 5 at the annual meeting of the American Society of Clinical Oncology (ASCO).

Dr. Dowlati found that patients with a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy. Dr. Dowlati analyzed data from a major national study, released at ASCO in 2005, that found the monoclonal antibody Bevacizumab (Avastin), in addition to standard treatment, was more effective than standard therapy alone for patients with advanced, non-squamous non-small cell lung cancer.

The analysis indicated that patients with low levels of ICAM (intercellular adhesion molecule -1), had a higher response rate to therapy (29% versus 13%) than patients with high ICAM levels. Patients with low ICAM levels also had a significantly better overall survival rate.

"We believe this research confirms a significant new prognostic marker in lung cancer," says Dr. Dowlati, who is also assistant professor at Case Western Reserve University School of Medicine. "Previously, it has been a challenge to identify those patients that will respond best to therapy and what their outcomes will be. This biomarker appears to serve as a much better predictor than gender, patients' overall health and sites of metastases." These findings confirm a pilot study performed three years ago at Ireland Cancer Center by Drs. Dowlati, Scot Remick and Keith McCrae, an expert in blood vessel disorders found in cancer.........

Posted by: Scott      Permalink         Source

June 1, 2006, 6:55 AM CT

Promising Results For Advanced Lung Cancer

Promising Results For Advanced Lung Cancer
An early phase study pairing an experimental targeted treatment with a common anti-inflammatory produced promising results in patients with advanced lung cancer, scientists at UCLA's Jonsson Cancer Center reported.

Pairing the targeted treatment Tarceva with the anti-inflammatory drug Celebrex increased response rates in lung cancer patients by about three-fold, said Dr. Karen Reckamp, an assistant professor of hematology/oncology and lead author of the study. The research appears in the June 1 issue of Clinical Cancer Research, the peer-reviewed journal of the American Association of Cancer Research.

Prior laboratory studies at UCLA showed that a cell signaling pathway known as COX-2 may be linked to resistance to drugs like Tarceva, which block tumor cell growth by targeting the protein EGFR, or epidermal growth factor receptor. Scientists theorized that giving Tarceva with Celebrex, a COX-2 inhibitor, would help battle resistance and prove to be an affective combination against lung cancer.

Typically, about 10 percent of lung cancer patients respond to Tarceva. In Reckamp's study of the combination treatment, about 33 percent of patients responded.

"Tarceva alone is a great drug and has a lot of clinical benefits, but for a small proportion of patients," Reckamp said. "With this drug combination, we saw an increase in response rates, indicating we are overcoming some resistance. We also may be beginning to understand the mechanisms of that resistance."........

Posted by: Scott      Permalink         Source

April 20, 2006, 0:15 AM CT

Cancer therapy based on anatomical location may soon be obsolete

Cancer therapy based on anatomical location may soon be obsolete
The results of a new study at Washington University School of Medicine in St. Louis could eventually have oncologists removing their specialties from their shingles by making treatment based on a tumor's anatomical location obsolete.

When the scientists compared eight different kinds of malignant tumors, they saw that whether the tumor was, for instance, a breast tumor, lung tumor or colon tumor didn't correlate to how the cancers interacted with a standard anticancer drug.

Their findings suggest that traditional cancer therapys - which have established different drug regimens for brain, prostate or ovary cancer, for example - should eventually be replaced with therapies that use drugs deemed to be of highest benefit based on the tumor's pharmacologic profile. Treatment choice would be determined by how each patient's tumor reacts to anticancer drugs, regardless of the tumor's anatomical origin.

"This study is the first time the pathway for a drug's effect has been analyzed in tumors from different anatomical locations," says Howard McLeod, Pharm.D., director of the pharmacology core at the Siteman Cancer Center and a member of the National Institutes of Health (NIH) Pharmacogenetics Research Network. "We've shown that drug effect is independent of where the tumor came from in the body. If further studies confirm that a tumor-specific approach is better than the current anatomical emphasis, oncologists may have to stop thinking of themselves as colon cancer or breast cancer specialists and let the cancer tell them which drugs to use for each specific patient."........

Posted by: Janet      Permalink         Source

April 17, 2006, 10:28 PM CT

Smoking May Cause Far More Cancer Deaths In Asian Americans

Smoking May Cause Far More Cancer Deaths In Asian Americans
Korean, Chinese, Japanese, and Vietnamese American males living in California die of cancer at three times the rate of South Asian females in California, whose cancer mortality rate is one of the lowest in the world.

As per a new study by UC Davis Cancer Center researchers, such disparities between genders and Asian and Pacific Islander ethnic groups can be explained almost entirely by tobacco smoke exposure - suggesting that if smoking were eliminated, Asian and Pacific Islander Americans all would have very low cancer mortality rates, with minimal variation from group to group.

"Among Asian Americans and Pacific Islanders, non-lung cancer death rates, like lung cancer death rates, correlate very closely with their smoke exposures," said Bruce N. Leistikow, associate professor of public health sciences at UC Davis and a leading expert on the epidemiology of smoking-related illnesses. "If all Asian and Pacific Islander Americans had as little smoke exposure as South Asian females in California, our work suggests that their cancer mortality rates across the board could be as low as that of the South Asian females."

South Asian females in California had a cancer mortality rate of 58 deaths per 100,000 people per year. The cancer mortality for the United States as a whole was 193.5.........

Posted by: Janet      Permalink         Source

April 12, 2006, 5:51 PM CT

Looking For Participant For An Online Survey Of Cancer Blogs

Looking For Participant For An Online Survey Of Cancer Blogs

Deborah S. Chung, Ph.D. who is Assistant Professor at University of Kentucky School of Journalism and Telecommunications has contacted me about an online survey for cancer patients. This is a study about cancer blog use by cancer patients.

The purpose of this study is to describe characteristics of cancer blog users and their motivations for visiting cancer blogs. In addition, this study hopes to assess behavioral changes after using cancer blogs and to draw associations between everyday use of media and use of cancer blogs.

This study will help cancer information seekers and healthcare providers alike understand how blogs as a new communication tool may potentially help cancer patients seek information and/or communication.

The information collected form this survey will be accessible only to the researchers. No personally identifiable information will be collected, and information will be presented in aggregate form. The survey will be collected on a server with SSL (Secure Sockets Layer) capabilities, which is one of the best providers of Internet security available, but there is always a risk that a third party may intercept the survey answers.

There are no foreseeable risks associated to this study. However, if you feel uncomfortable answering the survey questions, you may choose to skip a question or withdraw from the study at any time.........

Posted by: Sherin      Permalink         Source

April 7, 2006, 6:59 AM CT

Pain Medications Prevent Cancer

Pain Medications Prevent Cancer
Results results from a new, five-year study is showing that regular use this popular group of prescription pain relievers may reduce the risk of breast cancer by up to 71 percent. In addition, these drugs may also benefit in the prevention of prostate, colon and lung cancers.

These study findings were reported in the recent annual meeting of the American Association for Cancer Research in Washington, D.C. The researchers have found significant chemopreventive effects against breast cancer with the regular use of Cox-2 inhibitors and other non-steroidal anti-inflammatory drugs. The study was conducted by Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine.

Dr. Randall Harris and colleagues conducted a large case-control study of Cox-2 inhibitors and studied their impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. COX-2 inhibitors are non-steroidal, anti-inflammatory drugs that specifically block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.

Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.........

Posted by: Janet      Permalink         Source

Older Blog Entries   1   2   3   4   5   6   7   8   9  

Lung cancer
We engage a never-ending daily struggle to understand and defeat the hidden mysteries of cancer. This is a long and laborious fight, but some moments stand out as grim reminders of the severity of the problem and ruthlessness of the enemy. We recently heard about the sad demise of Peter Jennings, who was the news anchor of ABC News for a long time. Archives of lung-cancer-blog

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.